Literature DB >> 14981514

Bystander elimination of antigen loss variants in established tumors.

Michael T Spiotto1, Donald A Rowley, Hans Schreiber.   

Abstract

Cancers express antigens that are targets for specific cytotoxic T lymphocytes (CTLs). However, cancer cells are genetically unstable. Consequently, sub-populations of cancer cells that no longer express the target antigen may escape destruction by CTLs and grow progressively. We show that cytotoxic T cells indirectly eliminate these antigen loss variants (ALVs) in a model system when the parental cancer cells express sufficient antigen to be effectively cross-presented by the tumor stroma. When the parental tumor expressed lower levels of antigen, cytotoxic T cells eradicated the antigen-positive parental cancer cells, but the ALVs escaped, grew and killed the host. By contrast, when the parental tumor expressed higher levels of antigen, cytotoxic T cells eradicated not only the parental cancer cells but also the ALVs. This 'bystander' elimination of ALVs required stromal cells expressing major histocompatibility complex (MHC) molecules capable of presenting the antigen, and occurred in tumors showing evidence of stromal destruction. ALVs were apparently eliminated indirectly when tumor-specific CTLs killed stromal cells that were cross-presenting antigen produced by and released from antigen-positive cancer cells. These results highlight the general importance of targeting the tumor stroma to prevent the escape of variant cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981514     DOI: 10.1038/nm999

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  114 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

2.  Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.

Authors:  Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Heather C Flynn Gilmer; Darlene L Knutson; Richard G Vile
Journal:  Int J Cancer       Date:  2011-11-30       Impact factor: 7.396

3.  The manipulation of immunity. Conference on from allergy to cancer: new perspectives for therapeutic vaccination.

Authors:  Harald von Boehmer; Michel C Nussenzweig
Journal:  EMBO Rep       Date:  2004-07-16       Impact factor: 8.807

Review 4.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

5.  Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.

Authors:  Maria de la Luz Garcia-Hernandez; Hiromasa Hamada; Joyce B Reome; Sara K Misra; Michael P Tighe; Richard W Dutton
Journal:  J Immunol       Date:  2010-03-17       Impact factor: 5.422

Review 6.  Targeting cancer-specific mutations by T cell receptor gene therapy.

Authors:  Thomas Blankenstein; Matthias Leisegang; Wolfgang Uckert; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2015-02-27       Impact factor: 7.486

7.  Loss of S100 antigenicity in metastatic melanoma.

Authors:  Dara L Aisner; Ajay Maker; Steven A Rosenberg; David M Berman
Journal:  Hum Pathol       Date:  2005-09       Impact factor: 3.466

8.  Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity.

Authors:  Susan E Brophy; Lindsay L Jones; Phillip D Holler; David M Kranz
Journal:  Mol Immunol       Date:  2006-12-12       Impact factor: 4.407

9.  Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts.

Authors:  Xiuying Li; Yongsheng Wang; Yuwei Zhao; Hengxiu Yang; Aiping Tong; Chengjian Zhao; Huashan Shi; Yang Li; Zhenlin Wang; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-10       Impact factor: 4.553

Review 10.  Intravital imaging of CD8+ T cell function in cancer.

Authors:  Thorsten R Mempel; Christian A Bauer
Journal:  Clin Exp Metastasis       Date:  2008-07-30       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.